Recombinant yellow fever virus Env protein(aa 1-445) [His]

Name: Recombinant yellow fever virus Env protein(aa 1-445) [His]
SKU: DAG-833
Rating: 5 (1 reviews)

Yellow fever virus Env protein (aa 445), recombinant protein from E. coli

COA

SDS

Datasheet

Summary

Nature

Recombinant

Tag/Conjugate

His

Molecular Weight

50 kDa

Alternative Names

Yellow fever virus envelope protein; Yellow fever virus E protein; YFV E protein; YFV envelope protein

Purity

>95%

Format

Liquid

Concentration

Batch dependent - please inquire should you have specific requirements

Buffer

50 mM Tris-HCl, 8M urea, 0.5 mM EDTA, 5 mM b-Mercatoethanol, 0.25 M NaCl and 0.25 M imidazole

Preservative

None

Storage

Short-term: unopened, undiluted vials for less than a week at 4°C. Long-term: at –20°C or below in suitable aliquots after reconstitution. Do not freeze and thaw and store working, diluted solutions.

Antigen Description

The YFV genome is an 11kb single-stranded positive-sense RNA genome coding for a polyprotein, which is post- and co-translationally processed into three structural proteins and seven non-structural proteins. The largest of the structural proteins, the envelope (E) protein (445aa), is the major component of the virion surface. It is the primary immunogen and plays a central role in receptor binding and membrane fusion. It is the primary immunogen and plays a central role in receptor binding and membrane fusion.

Keywords

Yellow fever virus; Envelope protein; E protein

Citations

Have you cited DAG-833 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Substituted benzimidazoles: antiviral activity and synthesis of nucleosides

ARKIVOC

Authors: Budow, Simone; Kozlowska, Mariola; Gorska, Agata; Kazimierczuk, Zygmunt; Eickmeier, Henning; La Colla, Paolo; Gosselin, Gilles; Seela, Frank

Abstract

The antiviral activity of a series of benzimidazole derivatives and substituted benzimidazole beta-L- and beta-D-2'-deoxyribonucleosides against selected RNA and DNA viruses including HIV-1, BVDV, YFV, DENV-2, WNV, HBV, HCV and human RSV was evaluated. In addition, the synthesis of several benzimidazole beta-L-2'-deoxyribonucleosides (1-4) and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl nucleoside 5 is described. The stereoselective glycosylation of the anions of the functionalized benzimidazoles 6a, 12a and 28 with 3,5-di-O-(4-methylbenzoyl)-2-deoxy-alpha-L-erythro-pentofuranosyl chloride (29) furnished beta-L-2'-deoxyribonucleosides 1-4 while the glycosylation of the anion of 2-bromobenzimidazole (12a) with 3,5-di-O-benzoyl-2-deoxy-2-fluoro-alpha-D-arabinofuranosyl bromide 34 gave the 2'-deoxy-2-fluoro-beta-D-arabinofuranosyl nucleoside 5. Moreover, the crystal structure of the benzoylated 2-bromobenzimidazole 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl nucleoside 35 is reported.

Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe

TRENDS IN MICROBIOLOGY

Authors: Douam, Florian; Ploss, Alexander

Abstract

Yellow fever (YF) was one of the most dangerous infectious diseases of the 18th and 19th centuries, resulting in mass casualties in Africa and the Americas. The etiologic agent is yellow fever virus (YFV), and its live-attenuated form, YFV-17D, remains one of the most potent vaccines ever developed. During the first half of the 20th century, vaccination combined with mosquito control eradicated YFV transmission in urban areas. However, the recent 2016-2018 outbreaks in areas with historically low or no YFV activity have raised serious concerns for an estimated 400-500 million unvaccinated people who now live in at-risk areas. Once a forgotten disease, we highlight here that YF still represents a very real threat to human health and economies. As many gaps remain in our understanding of how YFV interacts with the human host and causes disease, there is an urgent need to address these knowledge gaps and propel YFV research forward.